Cosentyx could help multiple sclerosis in psoriasis patients

[Fred]

This study suggests Cosentyx (secukinumab) could help multiple sclerosis in patients with psoriasis.

Quote:

---

Background:
According to the literature, a significant association between multiple sclerosis and psoriasis has been reported. Among the various drugs used to treat psoriasis, tumor necrosis factor (TNF)‐α inhibitors seemed to increase the incidence of demyelinating diseases while IL‐17A inhibitors seemed to reduce the activity of multiple sclerosis.

Objectives:
The aim of this study is to find out if the use of Secukinumab in patients with psoriasis and multiple sclerosis would be both beneficial and safe.

Methods:
A 45‐years‐old woman affected by psoriasis and psoriatic arthritis was diagnosed with multiple sclerosis during the treatment for psoriasis. She performed follow‐up visits at the Dermo‐Rheuma Center of Spedali Civili Hospital in Brescia and, after several different therapies, was finally treated with Secukinumab. Outpatient follow‐up visits were performed every two months valuating PASI, joint involvement with CASPAR and DAPSA score and the neurological state with a clinical evaluation and magnetic resonance imaging.

Results:
A significant improvement of both psoriasis and psoriatic arthritis was observed with Secukinumab 300 mg administered monthly. PASI 75 was reached at 4 weeks of therapy, PASI 90 at 6 weeks and PASI 100 at 12 weeks. At 24 months of treatment PASI 100 was still maintained, no neurological symptoms were reported and multiple sclerosis remained stable over time.

Conclusions:
The blockade of IL‐17A with Secukinumab could be a safe and very promising therapeutic option for patients with psoriasis and multiple sclerosis.

Source: onlinelibrary.wiley.com

*Early view funding unknown

[Caroline]

That is not totally amazing. They use Tecfidera also for MS, which moderates the same IL-17. So indeed why would Psoriasis aimed bio’s not help with ms.